carvedilol has been researched along with glycerophosphoinositol 4,5-bisphosphate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aréchiga-Figueroa, IA; de Boer, TP; Ferrer, T; López-Izquierdo, A; Ponce-Balbuena, D; Sánchez-Chapula, JA; van der Heyden, MA | 1 |
| Ibrahim, IAAE; Ibrahim, WS; Mahmoud, AAA; Mahmoud, MF | 1 |
| Abd El Motteleb, DM; Elshazly, SM; Mohamed, RMSM; Nafea, OE | 1 |
3 other study(ies) available for carvedilol and glycerophosphoinositol 4,5-bisphosphate
| Article | Year |
|---|---|
Carvedilol inhibits Kir2.3 channels by interference with PIP₂-channel interaction.
Topics: Carbazoles; Carvedilol; HEK293 Cells; Humans; Phosphatidylinositol 4,5-Diphosphate; Point Mutation; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Propanolamines; Protein Binding | 2011 |
Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling.
Topics: Animals; beta-Arrestin 2; Cardiomegaly; Carvedilol; Cytokines; Diet, High-Fat; Dietary Sugars; Disease Models, Animal; Fibrosis; Fructose; Insulin Resistance; Male; Mice; Myocytes, Cardiac; Phosphatidylinositol 4,5-Diphosphate; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling | 2020 |
Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4.
Topics: Animals; Apoptosis; Atenolol; beta-Arrestin 2; Blood Pressure; Cardio-Renal Syndrome; Cardiomegaly; Cardiotonic Agents; Carvedilol; Diacylglycerol Kinase; Disease Models, Animal; Kidney; Male; Myocardium; Nephrectomy; Phosphatidylinositol 4,5-Diphosphate; Rats, Wistar; Receptors, Adrenergic, beta-1 | 2021 |